{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:14:05Z","timestamp":1788012845672,"version":"build-2784847793"},"reference-count":18,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v104.40634","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:59:33Z","timestamp":1725278373000},"page":"adv40634","source":"Crossref","is-referenced-by-count":5,"title":["Bullous Pemphigoid that Developed During Nemolizumab Treatment for Atopic Dermatitis: Two Case Reports"],"prefix":"10.2340","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9176-3446","authenticated-orcid":false,"given":"Michie","family":"Katsuta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Kamide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-4011","authenticated-orcid":false,"given":"Yozo","family":"Ishiuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0125-8930","authenticated-orcid":false,"given":"Yoshimasa","family":"Nobeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"71818","doi-asserted-by":"crossref","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPSG. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med 2020; 383: 141-150.","DOI":"10.1056\/NEJMoa1917006"},{"key":"71819","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1917006","DOI":"10.1056\/NEJMoa1917006"},{"key":"71820","doi-asserted-by":"crossref","unstructured":"Watanabe Y, Ishiuji Y, Ogawa-Tominaga M, Katsuta M, Asahina A. Real-world clinical efficacy of nemolizumab in Japanese patients with atopic dermatitis. Itch 2023; 33: 691-692.","DOI":"10.1097\/itx.0000000000000071"},{"key":"71821","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/itx.0000000000000071","DOI":"10.1097\/itx.0000000000000071"},{"key":"71822","doi-asserted-by":"crossref","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPaSG. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 2022; 186: 642-651.","DOI":"10.1111\/bjd.20873"},{"key":"71823","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/bjd.20873","DOI":"10.1111\/bjd.20873"},{"key":"71824","doi-asserted-by":"crossref","unstructured":"Masuyuki R, Sato E, Imafuku S. A case of bullous pemphigoid following administration of anti-IL-31 receptor A antibody. J Dermatol 2024 Mar 20 [Online ahead of print].","DOI":"10.1111\/1346-8138.17171"},{"key":"71825","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/1346-8138.17171","DOI":"10.1111\/1346-8138.17171"},{"key":"71826","doi-asserted-by":"crossref","unstructured":"Marazza G, Pham HC, Sch\u00e4rer L, Pedrazzetti PP, Hunziker T, Tr\u00fceb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol 2009; 161: 861-868.","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"71827","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2133.2009.09300.x","DOI":"10.1111\/j.1365-2133.2009.09300.x"},{"key":"71828","doi-asserted-by":"crossref","unstructured":"Tasanen K, Varpuluoma O, Nishie W. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid. Front Immunol 2019; 10: 1238.","DOI":"10.3389\/fimmu.2019.01238"},{"key":"71829","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fimmu.2019.01238","DOI":"10.3389\/fimmu.2019.01238"},{"key":"71830","doi-asserted-by":"crossref","unstructured":"R\u00fcdrich U, Gehring M, Papakonstantinou E, Illerhaus A, Engmann J, Kapp A, et al. Eosinophils are a major source of interleukin-31 in bullous pemphigoid. Acta Derm Venereol 2018; 98: 766-771.","DOI":"10.2340\/00015555-2951"},{"key":"71831","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2340\/00015555-2951","DOI":"10.2340\/00015555-2951"},{"key":"71832","doi-asserted-by":"crossref","unstructured":"Fassett MS, Braz JM, Castellanos CA, Salvatierra JJ, Sadeghi M, Yu X, et al. IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis. Sci Immunol 2023; 8: eabi6887.","DOI":"10.1126\/sciimmunol.abi6887"},{"key":"71833","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1126\/sciimmunol.abi6887","DOI":"10.1126\/sciimmunol.abi6887"},{"key":"71834","doi-asserted-by":"crossref","unstructured":"Kakinuma T, Wakugawa M, Nakamura K, Hino H, Matsushima K, Tamaki K. High level of thymus and activation-regulated chemokine in blister fluid and sera of patients with bullous pemphigoid. Br J Dermatol 2003; 148: 203-210.","DOI":"10.1046\/j.1365-2133.2003.05066.x"},{"key":"71835","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1365-2133.2003.05066.x","DOI":"10.1046\/j.1365-2133.2003.05066.x"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40634\/47536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40634\/47536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T11:59:40Z","timestamp":1725278380000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/40634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":18,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.40634","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,2]]}}}